Home
Resources
Publications
Plazomicin Is Active Against Metallo-β-Lactamase-Producing Enterobacteriaceae

Plazomicin Is Active Against Metallo-β-Lactamase-Producing Enterobacteriaceae

Alisa W Serio, Tiffany Keepers, Kevin M Krause

Open Forum Infect Dis. 2019 Mar 12;6(4):ofz123.

PMID: 30968059

Abstract:

Plazomicin is an aminoglycoside that was approved in June 2018 by the US Food and Drug Administration for the treatment of complicated urinary tract infections, including pyelonephritis, due to Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Proteus mirabilis. Plazomicin was engineered to overcome the most common aminoglycoside resistance mechanism, inactivation by aminoglycoside-modifying enzymes, but is not active against the less common 16S ribosomal RNA methyltransferases (16S-RMTase), which confer target site modification. As an aminoglycoside, plazomicin maintains activity against Enterobacteriaceae that express resistance mechanisms to other antibiotic classes, including metallo-β-lactamases. Therefore, in the absence of a 16S-RMTase, plazomicin is active against metallo-β-lactamase-producing Enterobacteriaceae.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR42410681	Inactivated Proteus mirabilis			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: